Denali Therapeutics Inc.

DNLI · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders9.1%

Institutions101.4%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$0	$330.53M	$105.06M	$48.66M	$335.56M	$26.68M	$129.16M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$555.34M	-$487.34M	-$196.70M	-$340.74M	-$295.75M	$62.72M	-$213.18M	-$46.37M
Operating income as a percentage of revenue.	–	–	-59.5%	-324.3%	-607.8%	18.7%	-799.1%	-35.9%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$512.54M	-$422.77M	-$145.22M	-$325.99M	-$290.58M	$71.14M	-$197.61M	-$36.24M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.97	$-2.57	$-1.06	$-2.60	$-2.39	$0.65	$-2.00	$-0.39
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.97	$-2.57	$-1.06	$-2.60	$-2.39	$0.63	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$205.33M	$174.96M	$127.11M	$218.04M	$293.48M	$507.14M	$79.45M	$77.12M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.14B	$1.37B	$1.15B	$1.46B	$1.40B	$1.60B	$553.23M	$661.98M
Everything the company owes — debt, unpaid bills, and other obligations.	$131.09M	$144.50M	$122.96M	$417.81M	$441.87M	$453.75M	$158.34M	$115.14M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.01B	$1.23B	$1.03B	$1.04B	$962.29M	$1.15B	$394.89M	$546.85M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$412.60M	-$347.69M	-$357.99M	-$244.72M	-$211.39M	$416.15M	-$151.58M	$50.12M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$9.50M	$15.91M	$12.94M	$17.83M	$8.50M	$3.10M	$17.92M	$3.39M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$422.10M	-$363.61M	-$370.93M	-$262.55M	-$219.89M	$413.06M	-$169.50M	$46.72M

	You	Peer avg
P/E	–	30.4
Revenue Growth	–	-29.5%
ROE	-54.9%	-48.1%

Denali Therapeutics Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison